PacketFabric Democratizes Cloud Connectivity Pricing
9.12.2020 17:15:00 EET | Business Wire | Press release
PacketFabric, an innovator of on-demand connectivity to the secure, private internet, today announced it launched flat rate pricing for hybrid cloud connectivity across the U.S. and Europe. With this innovative pricing strategy, PacketFabric continues to lead the market disruption of networking and cloud computing.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201209005337/en/
“They say you can’t have it good, fast and cheap, but now you can have all three with PacketFabric’s flat rate, cloud connectivity pricing,” said PacketFabric CEO, Dave Ward. (Graphic: Business Wire)
PacketFabric’s new democratized pricing is $100 per month for hosted hybrid cloud connections up to 1Gbps, for both metro and long-haul capacity in the United States and Europe. With this new pricing strategy, PacketFabric is making cloud connectivity egalitarian across the tech landscape.
“Cloud is the future, and it shouldn’t be exclusive,” said PacketFabric CEO Dave Ward. “That’s why we sought a way to democratize it. Now with PacketFabric’s flat rate pricing, companies from emerging businesses to large enterprises can have affordable access to the cloud.”
According to Gartner, “cost optimization will be crucial to drive cloud adoption, and by 2024, all legacy applications will be migrated to public cloud infrastructure.”
“They say you can’t have it good, fast and cheap, but now you can have all three with PacketFabric’s flat rate, cloud connectivity pricing,” continued Ward. “We’ve been disrupting the market since we launched PacketFabric’s Network-as-a-Service (NaaS) platform in 2017, and we continue to lead the way forward.”
PacketFabric’s NaaS orchestrates and guarantees connectivity between collocation facilities, clouds, and offers private network interconnection across the globe. The NaaS platform is private, secure, reliable and scalable, plus it’s fully redundant. PacketFabric is a women-founded technology start-up, launched by industry veterans Jezzibell Gilmore, PacketFabric’s Chief Commercial Officer, and Anna Claiborne, Senior Vice President of Product and Engineering for PacketFabric.
Ward, a prolific technologist, expands on PacketFabric’s strategy in his recent blog post, “Democratizing Access to the Cloud, Disrupting the Business of Getting to the Cloud.”
About PacketFabric
PacketFabric redefines how the enterprise moves data by automating network connectivity services. Leveraging an entirely automated SDN-based network architecture and the latest in optical and packet switching technology, PacketFabric enables dynamic, real-time connectivity services between more than hundreds of premier colocation facilities across many global markets. The PacketFabric Network-as-a-Service (NaaS) platform delivers simple, cost-effective, and scalable network deployment via its advanced Application Program Interface (API) and web portal. PacketFabric was named one of the “10 Hottest Networking Startups in 2020” by CRN and a 2020 “Cool Vendor in Enhanced Internet Services and Cloud Connectivity” by Gartner. PacketFabric investors include NantWorks and Digital Alpha Advisors. For more information, visit packetfabric.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201209005337/en/
Contact information
Media Contact:
Lauren de la Fuente
VP Marketing, PacketFabric
310-283-8488
lauren.delafuente@packetfabric.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Azafaros to Present at BIO International Convention 202615.6.2026 08:00:00 EEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 07:05:00 EEST | Press release
Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integration, Black Recon allows crews to launch, operate, recover, and recharge up to three unmanned aerial systems without leaving their platform, reducing risk and accelerating decision-making. “Black Recon
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom